Quad‐class exposed/refractory myeloma is associated with short survival-Reference-Cited by-同舟云学术

Quad‐class exposed/refractory myeloma is associated with short survival

Published:2023-10-13 Issue:1 Volume:204 Page:186-190
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Piron Bénédicte¹^ORCID,Costes‐Tertrais Domitille¹,Gastinne Thomas¹,Fourmont Aude Marie¹,Dubruille Viviane¹,Blin Nicolas¹,Moreau Philippe¹²³^ORCID,Touzeau Cyrille¹²³^ORCID,Tessoulin Benoit¹²^ORCID

Affiliation:

1. Department of Hematology University Hospital Nantes France

2. CRCINA, INSERM, CNRS Université d'Angers, Université de Nantes Nantes France

3. Site de Recherche Intégrée sur le Cancer (SIRIC) «ILIAD» INCA‐DGOS‐Inserm_12558 Nantes France

Abstract

SummaryVery scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti‐CD38 monoclonal antibody and therapies targeting B‐cell maturation antigen (BCMA) (Quad‐class exposed [QCE]). In this retrospective single‐centre study, we determined progression‐free survival (PFS) and overall survival (OS) from anti‐BCMA failure in 45 QCE patients. Seven (16%) patients received antibody‐drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR‐T cell. Thirty patients (67%) received ≥1 subsequent line of treatment. PFS was 4.4 months (95% CI = 2.4–12.5) and OS 6.3 months (95% CI = 3.9–14.4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need.

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19148

Reference14 articles.

1. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

2. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

3. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

4. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

5. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma;European Journal of Haematology;2024-06-18

2. Targeting GPRC5D in multiple myeloma;Expert Review of Anticancer Therapy;2024-04-16